Firazyr (icatibant) is a prescription drug that’s used to treat severe, sudden symptoms of hereditary angioedema (HAE). The drug comes as a liquid solution that’s injected under the skin as a one-time ...

Firazyr (icatibant) is a prescription injection that’s used to treat sudden swelling episodes caused by hereditary angioedema (HAE). These episodes are also called HAE attacks. Injection site ...

As with other drugs, Firazyr (icatibant) can cause side effects, such as injection site reactions and fever. If you cannot tolerate the side effects of Firazyr, talk with your doctor or pharmacist.

The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18 years and ...

Firazyr Available Soon for Acute Attacks of Hereditary Angioedema Shire announced that Firazyr (icatibant injection), a selective bradykinin B2 receptor antagonist, has been approved for the treatment ...

LONDON, Dec 1 (Reuters) - Pharmaceutical firm Shire Plc said it was a step closer to receiving U.S. approval for its Firazyr drug to treat hereditary angioedema after positive results from the largest ...

Dublin, Ireland and Lexington, Massachusetts, US - August 25, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug ...

Patients with acute attacks of hereditary angioedema who are 18 years of age and older will soon have a new generic treatment option. The Food and Drug Administration has approved Cipla’s Icatibant ...

European regulators have approved a label extension for Shire’s Firazyr, broadening its use include adolescents and children aged two years and older with a particular type of HAE. European regulators ...

Shire announced topline results from FAST-3, the largest of its Phase 3 trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE). The FAST-3 (For ...

Shire Receives European Approval for Label Extension of FIRAZYR ® (icatibant injection) for the Symptomatic Treatment of Acute Hereditary Angioedema (HAE) Attacks in Paediatric Patients FIRAZYR is the ...

Firazyr (icatibant acetate) is a brand-name drug that’s prescribed for hereditary angioedema (HAE) in adults. Firazyr comes as a subcutaneous injection that’s used when needed to treat an HAE attack.